The new vaccines are based on 'InVacc' platform that consists of a chain of amino acids attached to a gene of the virus being vaccinated against.
This genetic cocktail is then inserted into an incapacitated flu-like virus such as the adenovirus and injected into the body, where it triggers a broader and more aggressive immune response, enabling the immune system to quickly seek out and destroy the disease when it invades.
The original DNA vaccines - the precursor of the present platform - consist of a single gene taken from the virus or bacteria against which protection is sought and is injected into the body.
DNA vaccines, however, have so far been ineffective because, in practice, they generate too few of the all-important antigens - the 'alarm bells' that warn the immune system of attack.
This is because DNA vaccines are unable to fully decode their contents and deliver their message to the immune system.
The scientists behind InVacc, however, have come up with a means to overcome this problem. Their key innovation - the chain of amino acids inserted into the adenovirus - promotes the decoding of the new vaccines and ensures that more of the antigens are shown to the immune system
"The delivery mechanism provided by the amino acids is important for several reasons. First, the amino acid chain enables the vaccines to activate different profiles of attack cells", said Associate Professor Jan Pravsgaard, the lead scientist behind the project.
"Second, it picks up more of the important genetic information from the inner compartment of the virus or bacterium - where for our purposes - the crucial DNA material is based.
"Attaching DNA strands from the interior of the virus to the amino acid chain is crucial to developing stable vaccines, since it gives the immune system solid data on the nature of the threat it is faced with, even after the virus or bacteria has mutated," he added.
The scientists predict that the new platform will protect against the vast majority of viruses and bacteria, where a gene can be identified and targeted with a DNA vaccine.
Certain cancers such as skin cancer which have a genetic basis and/or a viral profile (e.g. cervical cancer begins with infection by the human papillomavirus) would also be candidates for the vaccines.